P
ProHub
English 简体中文 繁體中文
Medium Merger & Acquisition Growth Strategy Profitability

Drugs “R” Us

#Healthcare #Retail
ProHub Comment

This is a structured M&A case requiring candidates to build a revenue-focused framework and perform quantitative analysis. The key insight is recognizing that the acquisition adds only ~$1.8B in pharmaceutical revenue against a target of ~$16.1B (20% growth on RX Co's ~$14B baseline), making the deal insufficient on its own. Strong candidates distinguish between total US stores and NW region stores, explore revenue sources (RX vs. Front-of-House Merchandise), and identify strategic risks beyond pure financials.

Estimated Time 26 minutes
Difficulty Medium
Source Duke
10 / 100
Your client is RX Co, a pharmacy retailer with stores across the United States. To bolster their presence in the Pacific Northwest, they are in talks with Drug Corp to purchase retail assets in the region. Though the acquisition seems sound, the RX Co CEO wants to be sure that the transaction will help them achieve growth. Can you help the company evaluate the deal?

Clarifying Information

  1. RX Co aims to grow annual revenue by 20% from current levels. They want this to happen the first year after the acquisition is complete. Assume the acquisition can be completed and the assets operational in one year.
Mock Interview
Interviewer

Your client is RX Co, a pharmacy retailer with stores across the United States. To bolster their presence in the Pacific Northwest, they are in talks with Drug Corp to purchase retail assets in the region. Though the acquisition seems sound, the RX Co CEO wants to be sure that the transaction will help them achieve growth. Can you help the company evaluate the deal?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

RX Co, a national pharmacy retailer, is considering acquiring Drug Corp stores in the Pacific Northwest to achieve 20% annual revenue growth. The case requires candidates to evaluate deal viability by calculating whether the acquired stores’ pharmaceutical revenue can meet growth targets, identify gaps, and articulate strategic risks including sales cannibalization and regulatory complexity.

Key Insights:

  1. Revenue focus: This is explicitly a revenue case, not a profitability case—candidates must avoid cost analysis
  2. Geographic scope matters: Analysis must focus on NW region stores (RX: 5,000; Drug Corp: 900) not national totals
  3. Math validation: RX Co pharma revenue target ~$16.1B vs. acquisition contribution ~$1.8B reveals insufficient growth from deal alone
  4. MECE framework: Excellent candidates structure around revenue sources (Rx + Front-of-House Merchandise) and identify non-financial risks
  5. Strategic alternatives: Consider other avenues to reach revenue targets beyond this specific acquisition